CN102210844B - Chinese medicinal composition for treating chronic hepatitis and preparation method thereof - Google Patents
Chinese medicinal composition for treating chronic hepatitis and preparation method thereof Download PDFInfo
- Publication number
- CN102210844B CN102210844B CN2010101431266A CN201010143126A CN102210844B CN 102210844 B CN102210844 B CN 102210844B CN 2010101431266 A CN2010101431266 A CN 2010101431266A CN 201010143126 A CN201010143126 A CN 201010143126A CN 102210844 B CN102210844 B CN 102210844B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- chinese medicine
- radix
- medicine composition
- cornu cervi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a Chinese medicinal composition for treating chronic hepatitis and a preparation method thereof. The composition is prepared from the following Chinese herbal medicines: hairy antler, sulfur, melanterite, verdigris, borneol, walnut kernel, astragalus and the like. The Chinese medicinal composition has the effects of tonifying spleen and kidney, soothing liver, relieving stagnation and removing residual poison, can relieve the symptom of hepatitis obviously, promote hepatocyte growth, improve the clinical symptoms of patients who suffer from hepatitis obviously, promote the restoration of liver functions, shorten the course of disease, inhibit the duplication of deoxyribonucleic acid (DNA) of hepatitis B virus (HBV) and reduce the content of blood serum HBV-DNA, and has the obvious antiviral effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of treating chronic hepatitis and preparation method thereof, belong to technical field of Chinese medicines.
Background technology
Chronic hepatitis B is the healthy commonly encountered diseases of serious harm people, frequently-occurring disease, and developing the liver cirrhosis, the hepatocarcinoma that form thus is the main cause that causes patient death.At present hepatitis B virus is still lacked the efficacious therapy method, interferon has definite curative effect to it, but effective percentage is merely about 30%, and costs an arm and a leg, and side effect is big.The medicine of anti-hepatic fibrosis is also less at present, and uncertain therapeutic efficacy is cut.
The present invention provides a kind of warming the kidney and strengthening the spleen that has; Soothing the liver diffusing strongly fragrant; Removing dampness antidotal Chinese medicine composition, this Chinese medicine composition are used to treat chronic hepatitis B, anti-hepatic fibrosis has splendid effect, are superior to interferon when the cellular immunization of treatment chronic hepatitis B patients is unbalance.
Summary of the invention
The objective of the invention is to disclose a kind of Chinese medicine composition of treating chronic hepatitis.
The objective of the invention is to disclose a kind of method for preparing of treating the Chinese medicine composition of chronic hepatitis.
The objective of the invention is to realize through following technical scheme:
A kind of Chinese medicine composition of treating chronic hepatitis, said composition is processed by following raw medicaments in portion by weight:
Radix Astragali 2-10 weight portion Pulveratum Cornu Cervi Pantotrichum 15-40 weight portion
Sulfur (bean curd is processed) 1-6 weight portion Cornu Cervi Degelatinatum 1-6 weight portion
Rhizoma Zingiberis 3-9 weight portion Semen Juglandis 40-60 weight portion
Gypsum Fibrosum 8-25 weight portion Aerugo 1-6 weight portion
Radix Et Rhizoma Rhei 1-6 weight portion Pericarpium Citri Reticulatae Viride 3-9 weight portion
Fructus Jujubae 50 weight portion Melanteritum 1-6 weight portions
Fructus Toosendan 10 weight portion Radix Scutellariae 1-6 weight portions
Radix Glycyrrhizae 3-9 weight portion Herba Menthae 10-30 weight portion
Borneolum Syntheticum 1-6 weight portion Radix Scrophulariae 1-6 weight portion
Radix Aucklandiae 1-6 weight portion
Above-mentioned Chinese medicine composition is preferably processed like following bulk drugs:
The Radix Astragali 5 weight portion Pulveratum Cornu Cervi Pantotrichum 25 weight portions
Sulfur (bean curd is processed) 3 weight portion Cornu Cervi Degelatinatums 3 weight portions
Rhizoma Zingiberis 5 weight portion Semen Juglandis 50 weight portions
Gypsum Fibrosum 15 weight portion Aerugo 3 weight portions
Radix Et Rhizoma Rhei 3 weight portion Pericarpium Citri Reticulatae Virides 5 weight portions
Fructus Jujubae 50 weight portion Melanteritum 3 weight portions
Fructus Toosendan 10 weight portion Radix Scutellariaes 3 weight portions
Radix Glycyrrhizae 5 weight portion Herba Menthaes 20 weight portions
Borneolum Syntheticum 3 weight portion Radix Scrophulariaes 3 weight portions
The Radix Aucklandiae 2 weight portions.
Above-mentioned Chinese medicine composition is more preferably processed like following bulk drugs:
The Radix Astragali 9 weight portion Pulveratum Cornu Cervi Pantotrichum 18 weight portions
Sulfur (bean curd is processed) 5 weight portion Cornu Cervi Degelatinatums 2 weight portions
Rhizoma Zingiberis 8 weight portion Semen Juglandis 60 weight portions
Gypsum Fibrosum 10 weight portion Aerugo 5 weight portions
Radix Et Rhizoma Rhei 6 weight portion Pericarpium Citri Reticulatae Virides 8 weight portions
Fructus Jujubae 40 weight portion Melanteritum 5 weight portions
Fructus Toosendan 10 weight portion Radix Scutellariaes 5 weight portions
Radix Glycyrrhizae 5 weight portion Herba Menthaes 30 weight portions
Borneolum Syntheticum 3 weight portion Radix Scrophulariaes 5 weight portions
The Radix Aucklandiae 2 weight portions.
Compositions of the present invention can add adjuvant by common process and process clinical acceptable forms such as tablet, capsule, oral liquid, drop pill, granule; Said adjuvant comprises solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent, lubricant, substrate etc.
For above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.
The method for preparing of present composition pill is: except that Pulveratum Cornu Cervi Pantotrichum, sulfur, Aerugo, Melanteritum, Borneolum Syntheticum pulverize separately become fine powder; Semen Juglandis is ground into 13 flavor mixed powders such as the mud shape and the Radix Astragali is broken into fine powder; Sieve, grind with five tastes fine powder such as above-mentioned Pulveratum Cornu Cervi Pantotrichum and be mixed evenly, cross 100 mesh sieves.Every 100g powder adds refined honey 80g, processes big honeyed pills, promptly gets.
The present composition has strengthening spleen, tonifying kidney, dispersing the stagnated live-QI to relieve the stagnation of QI, expelling remnant toxicity function.Hepatitis symptom can be obviously alleviated, and hepatic cell growth can be promoted.The treatment hepatitis can obviously improve clinical symptoms, and can promote liver function recovery, shortens the course of disease, and obvious antivirus action is arranged, and can suppress duplicating of hepatitis B virus DNA, reduces serum HBV-dna content.
Following embodiment further specifies but is not limited to the present invention.
The specific embodiment
Embodiment 1
Take by weighing the following raw materials in weight medicine:
Radix Astragali 5g Pulveratum Cornu Cervi Pantotrichum 25g
Sulfur (bean curd is processed) 3g Cornu Cervi Degelatinatum 3g
Rhizoma Zingiberis 5g Semen Juglandis 50g
Gypsum Fibrosum 15g Aerugo 3g
Radix Et Rhizoma Rhei 3g Pericarpium Citri Reticulatae Viride 5g
Fructus Jujubae 50g Melanteritum 3g
Fructus Toosendan 10g Radix Scutellariae 3g
Radix Glycyrrhizae 5g Herba Menthae 20g
Borneolum Syntheticum 3g Radix Scrophulariae 3g
Radix Aucklandiae 2g
More than 19 flavors, remove Pulveratum Cornu Cervi Pantotrichum, sulfur, Aerugo, Melanteritum, Borneolum Syntheticum pulverize separately and become fine powder, Semen Juglandis is ground into 13 flavor mixed powders such as mud shape and the Radix Astragali is broken into fine powder, sieve, with five tastes fine powder such as above-mentioned Pulveratum Cornu Cervi Pantotrichum grind be mixed even, mistake 100 mesh sieves.Every 100g powder adds refined honey 80g, processes big honeyed pills, promptly gets.The heavy 3g of every ball.
Warming the kidney and strengthening the spleen, soothing the liver diffusing strongly fragrant, the removing dampness detoxifcation.Be applicable to that chronic hepatitis belongs to the spleen kidney deficiency, stagnation of liver-QI stasis, phlegm resistance person.Card meeting color is dark and gloomy or white all of a sudden, spiritlessness and weakness, and indigestion and loss of appetite abdominal distention, side of body rib dull pain, the side of body is mass in the abdomen down, and it is clear or yellowish urinate, big loose stool or not well, waist soreness, face neck vascular nevus or see liver palm, corpulent tongue is big, colour of the tongue is dim, tongue fur is white or be bored with.Stringy pulse and moistening or heavy string or stringy and thready pulse etc.Usage and consumption: oral, one time 1 ball once-a-day, or is followed the doctor's advice.
Clinical experiment
Data and method are divided into treatment group and matched group at random.Treatment group: male 62 examples, slight 19 examples of woman's 18 routine chronic hepatitis Bs, moderate 37 examples, severe 24 examples; The hepatitis course of disease 0.5～9 year, average 3.5 years.Matched group: male 59 examples, women 21 examples; 15～63 years old age, average 34 years old; 23 examples that chronic hepatitis B is slight, moderate 35 examples, severe 2 examples; The hepatitis course of disease 0.5～9 year, average 3 years.
Therapeutic Method: symptom, sign and biochemical indicator before two groups of patient treatments are all similar basically, do not have significance through statistical procedures difference.The diet of viewing duration, have a rest basic identical.Two groups of cases were all used quiet of Energy mixture 1 month, and take hepatoprotective and anti symptom treatment such as vitamin, oleanolic acid the full course of treatment, and the treatment group is taken above-mentioned pill, and every day 2 times, each 1 ball is swallowed after meal, and matched group is taken compound liver-benepitino remedy every day 3 times, each 4.
Observational technique: two groups of cases are unified criterion of therapeutical effect, are Prospective Study research.Except that 1 clinical symptoms of per unified observed and recordeds of 2 weeks (weak, poor appetite, abdominal distention, pain in the hepatic region, feel sick) and sign (jaundice, hepatomegaly); 1 liver function of per 4 weekly checks comprises serum glutamic pyruvic transminase (ALT), serum transpeptidase (r-GT), alkali phosphatase (AKP), total protein (TP), albumin, globulin ratio (A/G), serum total bilirubin simultaneously.Take medicine after preceding 3 months, the course of treatment finish, detect 1 HBVM (HBsAg, anti--HBs, HBeAg, anti--HBe, anti--HBc and HBV-DNA) respectively.
Therapeutic evaluation standard: 1. produce effects: after finishing the course of treatment, transference cure, serum A/G value normally, Serum ALT, TB IL reduce to normally; 2. effective: after finishing the course of treatment, remission, sign is improved, and the A/G value has recovery, and ALT reduces to below 25%; 3. invalid: after finishing the course of treatment, symptom, sign do not have improvement, and ALT does not descend or decline is arranged slightly.Statistical procedures: X
2Check.
The result: hepatitis clinical symptoms and sign are improved situation: hepatitis generally increases in treatment 3～4 week beginning appetite; Doing well,improvings such as weak, abdominal distention, poor appetite; After treating 1 course of treatment; Treatment group clinical symptoms, sign normalization rate: weak 89%, poor appetite 92%, abdominal distention 96%, with matched group relatively, difference has significance (P＜0.05).And the normalization rate of pain in the hepatic region, jaundice, hepatomegaly is respectively 82%, 97%, 89%, compares no significant difference (P＞0.05) with matched group.Liver function is improved situation: after treating 1 course of treatment, the hepatitis liver function is improved: 1. ALT treatment group improvement rate is: 91.25%; Matched group is: 71.25%, difference have significance 2. serum total bilirubin treatment group improvement rate be: 94%; Matched group is: 80%, two group of difference has significance.
The variation of HBVM: after treatment end half a year, treatment group patient and matched group patient HBeAg negative conversion rate are respectively 47.83% and 15.07%, and the HBV-DNA negative conversion rate is respectively 44.83% and 12.9%, and through statistical procedures, difference all has significance between two groups.
Embodiment 2.
Take by weighing following bulk drugs:
Radix Astragali 9g Pulveratum Cornu Cervi Pantotrichum 18g
Sulfur (bean curd is processed) 5g Cornu Cervi Degelatinatum 2g
Rhizoma Zingiberis 8g Semen Juglandis 60g
Gypsum Fibrosum 10g Aerugo 5g
Radix Et Rhizoma Rhei 6g Pericarpium Citri Reticulatae Viride 8g
Fructus Jujubae 40g Melanteritum 5g
Fructus Toosendan 10g Radix Scutellariae 5g
Radix Glycyrrhizae 5g Herba Menthae 30g
Borneolum Syntheticum 3g Radix Scrophulariae 5g
Radix Aucklandiae 2g;
More than 19 flavors, remove Pulveratum Cornu Cervi Pantotrichum, sulfur, Aerugo, Melanteritum, Borneolum Syntheticum pulverize separately and become fine powder, Semen Juglandis is ground into 13 flavor mixed powders such as mud shape and the Radix Astragali is broken into fine powder, sieve, with five tastes fine powder such as above-mentioned Pulveratum Cornu Cervi Pantotrichum grind be mixed even, mistake 100 mesh sieves.Every 100g powder adds refined honey 80g, processes big honeyed pills, promptly gets.The heavy 3g of every ball.
Research to the protective effect of chronic hepatic injury
Rat skin lower injection 10%5ml/kg carbon tetrachloride oil solution, 2 times weekly, injected continuously 3 months, cause carbon tetrachloride chronic hepatic injury animal model, observe the protective effect of medicine of the present invention to the damage liver.
Normal control group A and model control group B: normal saline is irritated stomach, irritates the medication capacity of stomach amount with medication therapy groups; Treatment group C: embodiment 1 pill, 2.7g/kg dosed administration; Treatment group D: embodiment 2 pills, 2.7g/kg dosed administration.Normal control group 16h behind the 12d injecting normal saline, the eyeball rear vein beard is got blood, and puts to death animal and get the hepatic tissue censorship; All the other organize 16h behind the intravenous injection lipopolysaccharide, and the eyeball rear vein beard is got blood, and put to death animal and get the hepatic tissue censorship.
To the protective effect of chronic hepatic injury rat (X ± SD)
| Group | n | Dosage | SGPT (Ka Menshi unit) | SGOT (Ka Menshi unit) | Hydroxyproline content |
| A | 10 | \ | 41.13±19.14 | 107.10±14.00 | 1.53±0.22 |
| B | 10 | \ | 270.61±98.20 | 360.10±71.13 | 2.13±0.25 |
| C | 10 | 2.7g/k g | 49.48±28.10 | 117.50±17.15 | 1.89±0.60 |
| D | 10 | 2.7g/k g | 39.39±15.90 | 69.18±16.20△ | 1.59±0.28 |
* compare △ P＜0.05 with the C group.
Can find out that from above result detecting qualified medicine of the present invention has significance to improve to ALT, ET, NO content in the hepatic injury mice serum, and chronic hepatic injury is had tangible protective effect, the prescription of embodiment 2 obviously is superior to the prescription of embodiment 1.
Embodiment 3
Take by weighing following bulk drugs:
Radix Astragali 9g Pulveratum Cornu Cervi Pantotrichum 18g
Sulfur (bean curd is processed) 5g Cornu Cervi Degelatinatum 2g
Rhizoma Zingiberis 8g Semen Juglandis 60g
Gypsum Fibrosum 10g Aerugo 5g
Radix Et Rhizoma Rhei 6g Pericarpium Citri Reticulatae Viride 8g
Fructus Jujubae 40g Melanteritum 5g
Fructus Toosendan 10g Radix Scutellariae 5g
Radix Glycyrrhizae 5g Herba Menthae 30g
Borneolum Syntheticum 3g Radix Scrophulariae 5g
Radix Aucklandiae 2g;
Process tablet through conventional technology.
Embodiment 4
Take by weighing following bulk drugs:
Radix Astragali 9g Pulveratum Cornu Cervi Pantotrichum 18g
Sulfur (bean curd is processed) 5g Cornu Cervi Degelatinatum 2g
Rhizoma Zingiberis 8g Semen Juglandis 60g
Gypsum Fibrosum 10g Aerugo 5g
Radix Et Rhizoma Rhei 6g Pericarpium Citri Reticulatae Viride 8g
Fructus Jujubae 40g Melanteritum 5g
Fructus Toosendan 10g Radix Scutellariae 5g
Radix Glycyrrhizae 5g Herba Menthae 30g
Borneolum Syntheticum 3g Radix Scrophulariae 5g
Radix Aucklandiae 2g;
Process capsule through conventional technology.
Embodiment 5
Take by weighing following bulk drugs:
Radix Astragali 9g Pulveratum Cornu Cervi Pantotrichum 18g
Sulfur (bean curd is processed) 5g Cornu Cervi Degelatinatum 2g
Rhizoma Zingiberis 8g Semen Juglandis 60g
Gypsum Fibrosum 10g Aerugo 5g
Radix Et Rhizoma Rhei 6g Pericarpium Citri Reticulatae Viride 8g
Fructus Jujubae 40g Melanteritum 5g
Fructus Toosendan 10g Radix Scutellariae 5g
Radix Glycyrrhizae 5g Herba Menthae 30g
Borneolum Syntheticum 3g Radix Scrophulariae 5g
Radix Aucklandiae 2g;
Process granule through conventional technology.
Claims (5)
1. Chinese medicine composition of treating chronic hepatitis is characterized in that said composition processed by following raw medicaments in portion by weight:
2. Chinese medicine composition as claimed in claim 1 is characterized in that sulfur is that bean curd is processed.
3. the method for preparing of Chinese medicine composition as claimed in claim 2 is characterized in that adding adjuvant by common process processes tablet, pill, capsule, oral liquid, granule.
4. method for preparing as claimed in claim 3; It is characterized in that becoming fine powder, Semen Juglandis is ground into 13 flavor mixed powders such as the mud shape and the Radix Astragali is broken into fine powder, sieve except that Pulveratum Cornu Cervi Pantotrichum, sulfur, Aerugo, Melanteritum, Borneolum Syntheticum pulverize separately; With five tastes fine powders such as above-mentioned Pulveratum Cornu Cervi Pantotrichum grind be mixed even; Sieve, powder adds refined honey and processes big honeyed pills, promptly gets.
5. the application of Chinese medicine composition as claimed in claim 1 in preparation treatment chronic viral hepatitis B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101431266A CN102210844B (en) | 2010-04-07 | 2010-04-07 | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101431266A CN102210844B (en) | 2010-04-07 | 2010-04-07 | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102210844A CN102210844A (en) | 2011-10-12 |
| CN102210844B true CN102210844B (en) | 2012-10-31 |
Family
ID=44742528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101431266A Active CN102210844B (en) | 2010-04-07 | 2010-04-07 | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210844B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106552243A (en) * | 2015-09-23 | 2017-04-05 | 刘从双 | A kind of Chinese patent medicine for treating hepatitis |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836388B (en) * | 2012-08-25 | 2014-01-08 | 李新欣 | Traditional Chinese medicine for chronic hepatitis treatment |
| EA020163B1 (en) * | 2012-10-04 | 2014-09-30 | Ооо "Эн.Си.Фарм" | Solid dosage form having a choleretic effect (variants) |
| EA020164B1 (en) * | 2012-10-04 | 2014-09-30 | Ооо "Эн.Си.Фарм" | Solid dosage form having a choleretic effect (variants) |
| EA020162B1 (en) * | 2012-10-04 | 2014-09-30 | Ооо "Эн.Си.Фарм" | Solid dosage form having a choleretic effect (variants) |
| EA020148B1 (en) * | 2012-10-04 | 2014-09-30 | Ооо "Эн.Си.Фарм" | Solid dosage form having a choleretic effect (variants) |
| CN105456535A (en) * | 2015-12-31 | 2016-04-06 | 青岛昌安达药业有限公司 | Traditional Chinese medicine decoction for treating chronic hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112838C (en) * | 1996-12-30 | 2003-06-25 | 皮埃尔·L·德罗什蒙特 | Ceramic composite wiring structure for semiconductor devices and method of manufacture thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1052889C (en) * | 1995-02-25 | 2000-05-31 | 北京朝阳丹肝病研究所 | Chinese proprietary for curing hepatitis |
-
2010
- 2010-04-07 CN CN2010101431266A patent/CN102210844B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112838C (en) * | 1996-12-30 | 2003-06-25 | 皮埃尔·L·德罗什蒙特 | Ceramic composite wiring structure for semiconductor devices and method of manufacture thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106552243A (en) * | 2015-09-23 | 2017-04-05 | 刘从双 | A kind of Chinese patent medicine for treating hepatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102210844A (en) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN105663607B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN101843694A (en) | Chinese medicament for treating chronic hepatitis | |
| CN102274417A (en) | Chinese patent medicament for treating aplastic anemia | |
| CN101926903A (en) | Chinese medicine preparation for curing facial paralysis | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN101632729B (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN1083269C (en) | Chinese herbal medicine for treating hysteromyoma and breast fibrosarcoma and its prepn. method | |
| CN112618656B (en) | Traditional Chinese medicine composition for treating climacteric syndrome of women and application thereof | |
| CN102813875B (en) | Traditional Chinese medicine composition for treating lupus erythematosus as well as application thereof | |
| CN111773292B (en) | Traditional Chinese medicine composition for treating herpes zoster as well as preparation method and application thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN101032613B (en) | Hepatic cyst-treating Chinese traditional medicine preparation and its preparation process | |
| CN108310111B (en) | Traditional Chinese medicine formula for benefiting qi and nourishing blood, preparation method and application thereof, medicated diet for benefiting qi and nourishing blood and preparation method thereof | |
| CN101244134B (en) | New purpose of naodesheng extract for treating diabetes complication | |
| CN106266968A (en) | Herba Artemisiae Scopariae liver heat removing choleretic granules and its preparation method and application | |
| CN104547945A (en) | Traditional Chinese medicine preparation for treating scrofula and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170526 Address after: Anguo City of Hebei province Baoding Yifeng Road No. 1 Patentee after: Beijing Ya Dong Biological Pharmaceutical Co. Ltd. (Yasukuni) Address before: 102200, 8, Zhenxing Road, Zhongguancun science and Technology Park, Beijing, Changping District Patentee before: Beijing Asia-East Bio-Pharmaceutical Co., Ltd. |